Pharmacokinetics and Safety of Single-dose Atogepant in Participants with Hepatic Impairment

被引：0
|
作者：
Boinpally, R. [1 ]
Jakate, A. [1 ]
Butler, M. [1 ]
Borbridge, L. [1 ]
Periclou, A. [1 ]
机构：
[1] Allergan Plc, Madison, NJ USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment
    Marshall, William L.
    Feng, Hwa-Ping
    Wenning, Larissa
    Garrett, Graigory
    Huang, Xiaobi
    Liu, Fang
    Panebianco, Deborah
    Caro, Luzelena
    Fandozzi, Christine
    Lasseter, Kenneth C.
    Preston, Richard A.
    Marbury, Thomas
    Butterton, Joan R.
    Iwamoto, Marian
    Yeh, Wendy W.
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (03) : 321 - 329
  • [2] Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment
    William L. Marshall
    Hwa-Ping Feng
    Larissa Wenning
    Graigory Garrett
    Xiaobi Huang
    Fang Liu
    Deborah Panebianco
    Luzelena Caro
    Christine Fandozzi
    Kenneth C. Lasseter
    Richard A. Preston
    Thomas Marbury
    Joan R. Butterton
    Marian Iwamoto
    Wendy W. Yeh
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 321 - 329
  • [3] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Vidya Perera
    Grigor Abelian
    Danshi Li
    Zhaoqing Wang
    Liping Zhang
    Susan Lubin
    Wei Chen
    Akintunde Bello
    Bindu Murthy
    [J]. Clinical Pharmacokinetics, 2022, 61 : 857 - 867
  • [4] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Perera, Vidya
    Abelian, Grigor
    Li, Danshi
    Wang, Zhaoqing
    Zhang, Liping
    Lubin, Susan
    Chen, Wei
    Bello, Akintunde
    Murthy, Bindu
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (06) : 857 - 867
  • [5] Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
    Boinpally, Ramesh
    Jakate, Abhijeet
    Butler, Matthew
    Borbridge, Lisa
    Periclou, Antonia
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 726 - 733
  • [6] Hepatic impairment does not alter the single-dose pharmacokinetics and safety of entecavir
    Bifano, M
    Yan, JH
    Xie, J
    Zhang, D
    Freund, J
    Grasela, D
    LaCreta, F
    [J]. ANTIVIRAL THERAPY, 2004, 9 (06) : H23 - H24
  • [7] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [8] Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
    Lawitz, Eric
    Parmar, Deven
    Momin, Taufik
    Shaikh, Farheen
    Patel, Harilal
    Hayes, Helen
    Swint, Kimberly
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12): : 1142 - 1155
  • [9] Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir.
    Bifano, M
    Yan, JH
    Xie, JD
    Zhang, DX
    Freund, J
    Hanna, G
    Lacreta, F
    Grasela, D
    [J]. HEPATOLOGY, 2004, 40 (04) : 663A - 663A
  • [10] Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment
    Sahasrabudhe, Vaishali
    Terra, Steven G.
    Hickman, Anne
    Saur, Didier
    Raje, Sangeeta
    Shi, Haihong
    Matschke, Kyle
    Zhou, Susan
    Cutler, David L.
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (10) : 1701 - 1710
12345